Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force.
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force.
复制标题
DOI：
10.1002/acr2.11220
复制
发表时间：
2021-03
影响因子：
3.4
通讯作者：
Broder A
中科院分区：
文献类型：
--
作者：
Ayesha B;Kumthekar A;Jain R;Patel S;Ramesh M;Ferastraoaru DE;Hudes G;Karagic M;Zafar S;Bartash R;Vasquez-Canizares N;Kitsis E;Tagoe C;Wahezi DM;Rubinstein T;Broder A
2019冠状病毒病（COVID - 19）患者可发展为一种称为细胞因子风暴综合征（CSS）的不受调节的炎症状态。我们描述了COVID - 19多学科咨询服务的形成和运作，该服务可以在大流行期间为COVID - 19重症患者提供个性化治疗。来自不同亚专业的机构专家在纽约州布朗克斯区蒙特菲奥雷医疗中心组成了一个COVID - 19 CSS工作组。他们就有助于早期识别COVID - 19 CSS的一套4个临床参数和6个实验室参数达成了一致。我们介绍了COVID - 19工作组的组成和实施情况。COVID - 19 CSS会诊队列的病例系列描述强调了会诊量、基线特征、临床和实验室参数，以及如何为这些患者分配生物治疗。2020年4月4日至5月7日期间，成立了COVID - 19 CSS工作组，由成人和儿童风湿病学家以及过敏和免疫学医生组成。该工作组共评估了288例患者，其中197例（68%）为男性，中位年龄（四分位间距[IQR]）为62岁（51 - 70），122例（42%）为西班牙裔，88例（31%）为黑人或非裔美国人。所有转诊患者的共同症状为呼吸困难（85%）和腹泻（80%）。31例接受生物治疗的患者年龄更小，中位（IQR）年龄为53（32‐63）岁，而非生物治疗组为62.5（52‐70）岁（P = 0.008）。在重症监护环境中接受生物制剂的比例更高（26例[84%]vs 151例[59%]；P = 0.006）。据我们所知，这是首个多学科合作项目，旨在为可能患有CSS的COVID - 19患者的评估和治疗提供个性化患者建议。该工作模型有助于设计一种方法，可以在缺乏循证指南的情况下确定最有可能从生物治疗中获益的患者。
Patients with coronavirus disease 2019 (COVID‐19) can progress to a state of unregulated inflammation called cytokine storm syndrome (CSS). We describe formation and operation of a COVID‐19 multidisciplinary consultation service that was allowed to individualize treatment for critically ill patients with COVID‐19 during the pandemic. Institutional experts from different subspecialties formed a COVID‐19 CSS task force at Montefiore Medical Center, Bronx, NY. They agreed on a set of four clinical and six laboratory parameters that can help early identify COVID‐19 CSS. We describe the formation and implementation of the COVID‐19 task force. The case series description of the COVID‐19 CSS consultation cohort highlights consultation volume, baseline characteristics, clinical and laboratory parameters, and how biologic treatments were allocated to these patients. Between April 4,2020, and May 7,2020, the COVID‐19 CSS task force was formed, consisting of adult and pediatric rheumatologists and allergy and immunology physicians. The task force evaluated a total of 288 patients, of whom 197 (68%) were male, the median (interquartile range [IQR]) age was 62 (51‐70) years, 122 (42%) were Hispanic, and 88 (31%) were Black or African American. The common presenting symptoms in all referred patients were dyspnea (85%) and diarrhea (80%). Thirty‐one patients who received biologic therapy were younger, with a median (IQR) age of 53 (32‐63) years, as opposed to 62.5 (52‐70) years in the nonbiologic group (P = 0.008). A higher proportion receiving biologics was in the critical care setting (26 [84%] vs 151 [59%]; P = 0.006). To the best of our knowledge, this is the first multidisciplinary collaborative effort to provide individualized patient recommendations for evaluation and treatment of patients with COVID‐19 who may have CSS. This working model helped to devise an approach that may have identified patients who were most likely to benefit from biologic therapy in the absence of evidence‐based guidelines.
登录
查看更多内容
影响因子：
4.2
作者：
Wong JP;Viswanathan S;Wang M;Sun LQ;Clark GC;D'Elia RV
通讯作者：
D'Elia RV
影响因子：
30.3
作者：
Channappanavar R;Fehr AR;Vijay R;Mack M;Zhao J;Meyerholz DK;Perlman S
通讯作者：
Perlman S
DOI：
10.1089/jir.2014.0227
发表时间：
2015-04
期刊：
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
影响因子：
--
作者：
Davidson S;Maini MK;Wack A
通讯作者：
Wack A
影响因子：
168.9
作者：
Zhou, Fei;Yu, Ting;Cao, Bin
通讯作者：
Cao, Bin
DOI：
10.1016/j.ijantimicag.2020.105954
发表时间：
2020-05-01
影响因子：
10.8
作者：
Zhang, Chi;Wu, Zhao;Wang, Gui-Qiang
通讯作者：
Wang, Gui-Qiang